EVACETRAPIB A hope in order to treat cardiovascular disease… * Laurent MAGNIES Claire JAGODZINSKI INTRODUCTION CV disease = 1st cause of death Statins: Introduction in…

Slide 1 HDL: Still a target for therapy? PaACC Annual Chapter Meeting November 2, 2008 Daniel J. Rader, MD University of Pennsylvania School of Medicine [email protected]…

Slide 1 HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? GARY A. LOPEZ, M.D. Slide 2 Disclosures None Slide 3 Atherosclerotic Heart Disease…

Slide 1 Pharmacology 301.6 Module 6 Lesson 2 Lipids/Obesity Slide 2 Lipid cycling Chylomicron metabolism HL = hepatic lipase LPL = lipoprotein lipase FFA = free fatty acids…

Slide 1 Obesity and Dyslipidemia AR Esteghamati, MD Associate Professor of Internal Medicine Endocrinology and Metabolism Research Center Tehran University of Medical Sciences…

Gender, Nutrigenomics and CVD Jose M Ordovas, PHD Director, Nutrition and Genomics Laboratory Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University…

HDL : a novel target in prevention ? De-risking the development programs of CETP inhibitors after the torcetrapib failure: Endothelial function & blood pressure Prof.…

Pharmacological Effects of Statins Overview Lipids and Lipoproteins Pharmacology of Statins How Do we Choose a Statin? Lipids and Lipoproteins Lipids Triglycerides Source:…

Obesity and Dyslipidemia Obesity and Dyslipidemia AR Esteghamati, MD Associate Professor of Internal Medicine Endocrinology and Metabolism Research Center Tehran University…

Roche Template The role of Phase I in the quest for “good”cholesterol - failure of the CETP modulator dalcetrapib Joint Conference 2013 of CPI | AGAH | BAPU | AHPPI Nice,…